Indolent Non-Hodgkin’s Lymphomas (iNHLs), including follicular lymphoma (FL) and marginal zone lymphoma (MZL), usually have a good prognosis, but are not curable with the therapeutic options that are currently available. FL and Marginal zone lymphoma MZL initially respond to therapy, but regularly lead to remissions and relapses. Over time, the lymphomas turn into a refractory state or become even more aggressive and difficult to manage.
Revive Research Institute is conducting a study to investigate the safety and effectiveness of an approved CD20 antibody immunotherapy in combination with a new investigational drug. Our goal is to demonstrate that this combination is superior to the standard immunochemotherapy in previously treated patients with FZ or Marginal zone lymphoma MZL.
- Adults 18 years of age or older, male or female
- Histologically confirmed diagnosis of CD20 positive iNHL
- Must have received one or more prior lines of anti-CD20 antibody therapy in combination with cytotoxic chemo or L
- Additional criteria may apply
Our group of licensed and certified physicians will be keeping track of the patient’s progress throughout the study and will address any concerns or queries that arise regarding the research trial. The investigational treatment is free for the duration of the clinical trial and insurance is not required. All patient records and information will be kept secure and confidential. The patient will also receive compensation for their time and involvement.